SPAS(SH:603168)2021-04-26 16:00Financial Performance - Operating revenue for the year-to-date was CNY 153,160,950.86, an increase of 125.59% year-on-year[7] - Net profit attributable to shareholders was CNY 10,488,392.31, representing a significant increase of 2,415.40% compared to the same period last year[7] - Basic earnings per share reached CNY 0.03, up 2,900.00% from CNY 0.001 in the previous year[7] - The total profit for Q1 2021 was ¥17.44 million, reflecting a significant increase of 1008.86% from ¥1.57 million in the previous year, driven by higher sales of eye drops and new service income from Taizhou Hospital[13] - Net profit for Q1 2021 was ¥10,488,392.31, compared to a net profit of ¥416,966.42 in Q1 2020, marking a substantial increase[31] - The company achieved a comprehensive income total of ¥10,488,392.31 for Q1 2021, significantly higher than ¥416,966.42 in Q1 2020[31] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 12,479,810.76, a decrease of 6.99% compared to the previous year[7] - The cash inflow from sales and services reached ¥160,405,215.88, a 44.7% increase from ¥110,892,358.98 in Q1 2020[36] - The net cash flow from operating activities for Q1 2021 was ¥12,479,810.76, a decrease of 7% compared to ¥13,418,137.83 in Q1 2020[37] - The total cash inflow from investment activities in Q1 2021 was ¥100,942,222.22, significantly up from ¥35,019,364.30 in Q1 2020, marking an increase of 187.5%[37] - The net increase in cash and cash equivalents for Q1 2021 was ¥112,622,702.82, compared to ¥38,609,399.93 in Q1 2020, indicating a rise of 191.5%[38] - The ending balance of cash and cash equivalents as of the end of Q1 2021 was ¥219,403,276.00, down from ¥262,098,707.42 at the end of Q1 2020[38] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,663,726,722.34, a decrease of 0.55% compared to the end of the previous year[7] - Current liabilities totaled CNY 342,328,243.00, down from CNY 361,918,221.00 in the previous period, indicating a reduction of approximately 5.5%[22] - The company reported a decrease in total liabilities from CNY 347,119,765.81 to CNY 366,784,743.81, indicating a reduction of approximately 5.4%[22] - The total equity attributable to shareholders reached CNY 1,316,606,956.53, up from CNY 1,306,118,564.22, showing a growth of about 0.2%[22] - The company's total current assets reached ¥654.99 million, slightly up from ¥647.65 million at the end of 2020, reflecting stable asset management[20] Shareholder Information - The number of shareholders at the end of the reporting period was 20,619[10] - The top shareholder, Chen Dekang, held 70,096,671 shares, accounting for 21.73% of the total shares[11] Research and Development - Research and development expenses surged by 192.20% to ¥11.64 million, mainly due to increased investment in the consistency evaluation of eye drops[13] - The company has initiated a leadership group to expedite the consistency evaluation of the eye drops, with nine institutions, including Sun Yat-sen University, having passed ethical review[14] Future Outlook - The company plans to continue its market expansion and product development strategies, focusing on enhancing the quality and efficacy of its eye drops[13][14] - The company has not reported any significant changes in net profit expectations for the upcoming reporting period[18]